Lactate-Buffered and Bicarbonate-Buffered Solutions with Less Glucose Degradation Products in a Two-Chamber System

Pastan S. , Bailey J. Dialysis therapy. N Engl J Med 1998; 338(20): 1428–36.

Jörres A. Bio-(in)-kompatibilität der peritonealdialyse. Dialyse-Journal 1996; 55: 103–8.

Bunchman T.E. , Ballal S.H. Treatment of inflow pain by pH adjustment of dialysate in peritoneal dialysis. Perit Dial Int 1991; 11: 179–80.

Yamamoto T. , Sakura T. , Yamakawa M. , Horiuchi N. , Hirata S. , Iritani Y. Clinical effects of long-term use of neutralised dialysate for continuous ambulatory peritoneal dialysis. Nephron 1992; 60: 324–9.

Daugirdas J.T. , Chaurdry A.H. , Ing I.L. Alkalinization of peritoneal dialysis solutions with sodium hydroxide or sodium bicarbonate. Artif Organs 1995; 12(3): 203–5.

Henderson I.S. , Couper I.A. , Lumsden A. Potentially irritant glucose metabolites in unused CAPD fluid. In: Maher J.F. , Winchester J.F. , eds. Frontiers in peritoneal dialysis. New York: Field, Rich and Associates, Inc.; 1986: 261–4.

Simonsen O. , Wieslander A. , Landgren C. , Rippe B. Less infusion pain and elevated level of cancer antigen 125 by the use of a new and more biocompatible PD fluid. In: Khanna R. , ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1996; 12: 156–60.

Topley N. , Coles G.A. , Williams J.D. Biocompatibility studies on peritoneal cells. Perit Dial Int 1994; 14(3): S21–8.

Duwe A.K. , Vas S.I. , Weatherhead J.W. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro. Infect Immun 1981; 33: 130–5.

Alscher D.M. , Magnus C. , Kirchgessner J. , Kuhlmann U. , Mettang T. Influence of different peritoneal fluids on function of leukocytes [Abstract]. In: Nephrology 1999. Proceedings of the XVth International Congress of Nephrology; 2–6 May 1999; Buenos Aires, Argentina. Buenos Aires; 1999: 442.

Alobaidi H.M. , Coles G.A. , Davies M. , Lloyd D. Host defence in continuous ambulatory peritoneal dialysis: The effect of the dialysate on phagocyte function. Nephrol Dial Transplant 1986; 1: 16–21.

van Bronswijk H. , Verbrugh H.A. , Heezius H.C. , van der Meulen J. , Oe P.L. , Verhoef J. Dialysis fluids and local host resistance in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 1988; 7: 368–73.

Ing B.L. , Gupta D.K. , Nawab Z.M. , Zhou F.Q. , Rahman M.A. , Daugirdas J.T. Suppression of neutrophil superoxide production by conventional peritoneal dialysis solution. Int J Artif Organs 1988; 11: 351–4.

Gordon D.L. , Rice J.L. , Avery V.M. Surface phagocytosis and host defence in the peritoneal cavity during continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 1990; 9: 191–7.

Yu A.W. , Zhou X.J. , Zhou F.Q. , Nawab Z.M. , Gandhi V.C. , Ing T.S. Neutrophilic intracellular acidosis induced by conventional, lactate-containing peritoneal dialysis solutions. Int J Art Organs 1992; 15: 661–5.

Liberek T. , Topley N. , Jörres A. , Petersen M.M. , Coles G.A. , Gahl G.M. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron 1993; 65: 260–5.

Douvdevani A. , Rapoport J. , Konforty A. , Yulzari R. , Moran A. , Chaimovitz C. Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages. J Am Soc Nephrol 1995; 6(2): 207–13.

Yamamoto T. , Sakakura T. , Yamakawa M. , Horiuchi N. , Hirata S. , Iritani Y. Clinical effects of long-term use of neutralized dialysate for continuous ambulatory peritoneal dialysis. Nephron 1992; 60: 324–9.

Wieslander A.P. Cytotoxicity of peritoneal dialysis fluid—Is it related to glucose breakdown products? Nephrol Dial Transplant 1996; 11: 958–9.

Wieslander A.P. , Andren A.H.G. , Nilsson–Thorell C. , Muscalu N. , Kjellstrand P.T.T. , Rippe B. Are aldehydes in heat-sterilized peritoneal fluids toxic in vitro? Perit Dial Int 1995; 15: 348–52.

Wieslander A. , Linden T. , Forsbäck G. , Henle T. , Deppisch R. 3-deoxyglucosone, a potential promotor of AGE, should be considered when developing new fluids for peritoneal dialysis [Abstract]. Perit Dial Int 1999; 19(Suppl 1): S86.

Jonasson P. , Bagge U. , Wieslander A. , Braide M. Heat-sterilized PD fluid blocks leukocyte adhesion and increases flow velocity of rat peritoneal venules. Perit Dial Int 1996; 16(Suppl 1): S137–40.

Witowski J. , Korybalska K. , Wisniewska J. , Breborowicz A. , Gahl G.M. , Frei U. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11: 729–39.

Millar D.J. , Dawnay A.B.S. Heat sterilization of PD fluid promotes advanced glycation end-product (AGE) formation [Abstract]. J Am Soc Nephrol 1995; 6: 551.

Nakayama M. , Kawaguchi Y. , Yamada K. , Hasegawa T. , Takazoe K. , Katoh N. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51: 182–6.

Honda K. , Nitta K. , Horita S. , Yumura W. , Nihei H. , Nagai R. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14: 1541–9.

Tauer A. , Schmitt R. , Knerr T. , Lage C. , Passlick–Deetjen J. , Pischetsrieder M. Formation of the glucose degradation product 3-deoxyglucosone and other carbonyl-compounds in single- or double-chamber peritoneal dialysis fluids [Abstract]. Perit Dial Int 2000; 20: 142.

Jörres A. , Witowski J. , Mauder B. , Gahl G.M. , Frei U. , Passlick–Deetjen J. Mesothelial biocompatibility of Balance, a novel two-chambered, lactate-buffered peritoneal dialysis solution [Abstract]. In: Nephrology 1999. Proceedings of the XVth International Congress of Nephrology; 2–6 May 1999; Buenos Aires, Argentina. Buenos Aires; 1999: 441.

Bender T.O. , Witowski J. , Passlick–Deetjen J. , Gahl G.M. , Frei U. , Jörres A. Reduced viability of human peritoneal mesothelial cells (HPMC) following “chronic” exposure to differently sterilized peritoneal fluids (PDF) [Abstract]. Perit Dial Int 2000; 20(Suppl 1): S9.

Feriani M. Bicarbonate-buffered CAPD solutions: From clinical trials to clinical practice. Perit Dial Int 1997; 17(Suppl 2): S51–5.

Feriani M. , Ronco C. , LaGreca G. Acid base balance with different CAPD solutions. Perit Dial Int 1996; 16(Suppl 1): S126–9.

Schmitt C.P. , Doetschmann R. , Passlick–Deetjen J. , Mehls O. , Schaefer F. Comparison of acid–base and solute transport kinetics in children using bicarbonate- vs lactate-buffered PD fluids [Abstract]. Perit Dial Int 1999; 19(Suppl 1): S75.

Feriani M. , Kirchgessner J. , LaGreca G. , Passlick–Deetjen J. , and the Bicarbonate CAPD Cooperative Group. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998; 54: 1731–8.

Feriani M. , Biasioli S. , Borin D. , Bragantini L. , Brendolan A. , Chiaramonte S. Bicarbonate buffer for CAPD solution. ASAIO Trans 1985; 31: 668–72.

Jörres A. , Gahl G.M. , Topley N. , Neubauer A. , Ludat K. , Müller C. In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions. Nephrol Dial Transplant 1994; 9: 785–90.

Jörres A. , Bender T.O. , Finn A. , Witowski J. , Fröhlich S. , Gahl G.M. Biocompatibility and buffers: Effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int 1998; 54: 2184–93.